EMA warns of possible medication errors when developing new forms and indications
This article was originally published in Scrip
Executive Summary
In yet another move spurred by the new EU pharmacovigilance legislation, companies proposing to market products similar to ones already on the market are being asked to take extra steps to prevent potential medication errors, particularly with substances that have a narrow therapeutic index.